165 related articles for article (PubMed ID: 29350484)
1. Paraptosis-Inducing Nanomedicine Overcomes Cancer Drug Resistance for a Potent Cancer Therapy.
Zhou Y; Huang F; Yang Y; Wang P; Zhang Z; Tang Y; Shen Y; Wang K
Small; 2018 Feb; 14(7):. PubMed ID: 29350484
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
Wang H; Li F; Du C; Wang H; Mahato RI; Huang Y
Mol Pharm; 2014 Aug; 11(8):2600-11. PubMed ID: 24405470
[TBL] [Abstract][Full Text] [Related]
3. Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells.
Ma YC; Wang JX; Tao W; Sun CY; Wang YC; Li DD; Fan F; Qian HS; Yang XZ
ACS Appl Mater Interfaces; 2015 Dec; 7(47):26315-25. PubMed ID: 26552849
[TBL] [Abstract][Full Text] [Related]
4. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
5. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
6. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
7. Micelle System Based on Molecular Economy Principle for Overcoming Multidrug Resistance and Inhibiting Metastasis.
Qi Y; Qin X; Yang C; Wu T; Qiao Q; Song Q; Zhang Z
Mol Pharm; 2018 Mar; 15(3):1005-1016. PubMed ID: 29397749
[TBL] [Abstract][Full Text] [Related]
8. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
9. Overcoming cellular multidrug resistance using classical nanomedicine formulations.
Kunjachan S; Błauż A; Möckel D; Theek B; Kiessling F; Etrych T; Ulbrich K; van Bloois L; Storm G; Bartosz G; Rychlik B; Lammers T
Eur J Pharm Sci; 2012 Mar; 45(4):421-8. PubMed ID: 21907796
[TBL] [Abstract][Full Text] [Related]
10. A novel 8-hydroxyquinoline derivative induces breast cancer cell death through paraptosis and apoptosis.
Ma L; Xuan X; Fan M; Zhang Y; Yuan G; Huang G; Liu Z
Apoptosis; 2022 Aug; 27(7-8):577-589. PubMed ID: 35674852
[TBL] [Abstract][Full Text] [Related]
11. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
[TBL] [Abstract][Full Text] [Related]
12. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
13. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
[TBL] [Abstract][Full Text] [Related]
14. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.
Sarisozen C; Dhokai S; Tsikudo EG; Luther E; Rachman IM; Torchilin VP
Eur J Pharm Biopharm; 2016 Nov; 108():54-67. PubMed ID: 27569031
[TBL] [Abstract][Full Text] [Related]
16. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
Shi Q; Zhang L; Liu M; Zhang X; Zhang X; Xu X; Chen S; Li X; Zhang J
Biomaterials; 2015 Oct; 67():169-82. PubMed ID: 26218743
[TBL] [Abstract][Full Text] [Related]
17. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
18. TPGS/Phospholipids Mixed Micelles for Delivery of Icariside II to Multidrug-Resistant Breast Cancer.
Song J; Huang H; Xia Z; Wei Y; Yao N; Zhang L; Yan H; Jia X; Zhang Z
Integr Cancer Ther; 2016 Sep; 15(3):390-9. PubMed ID: 26293804
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
20. Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines.
Wang K; Ramji S; Bhathena A; Lee C; Riddick DS
Xenobiotica; 1999 Feb; 29(2):155-70. PubMed ID: 10199592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
